Dr. UDAY TEKCHANDANI

Dr. USHA SINGH, Dr. Sameeksha Tadepalli, Dr.ADITI MEHTA GREWAL, Dr. USHA SINGH

Abstract

A retrospective review of retinoblastoma eyes receiving intravitreal chemotherapy for vitreous seeds between 2010 to 2019. All patients with a minimum of 5 months of follow up after receiving the last intravitreal injection were included. Post systemic chemotherapy, 9 eyes received intravitreal chemotherapy. At presentation, vitreous seeds were seen in the form of dust-3, cloud-4, and sphere-2. Eyes received either Melphalan or Topotecan (6) or both in 3. Dose ranged between 20 to 30 µg per injection with a mean of 3.8 per eye. At a mean follow up of 13.8 months response was seen as complete disappearance (1), inactive calcific seeds (3), inactive mixed regression (amorphous-calcific seeds 1), and persistent active seeds (4). Side effects were seen as retinal pigment epithelial mottling in 2, while one developed hypotony with cataract, iris atrophy, and iris bombe. Intravitreal chemotherapy is a useful treatment adjunct for the control of vitreous seeds, thereby improving globe salvage